Home › Stroke › North Carolina › Greensboro
Stroke clinical trials in Greensboro, NC
4 studies for Stroke are looking for participants at sites in and around Greensboro (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Low Dose ColchicinE in pAtients With Peripheral Artery DiseasE to Address Residual Vascular Risk
RecruitingPhase 3
- Moses Cone Hospital, Greensboro
Safety in Adult Participants With Atrial Fibrillation Who Are Treated With Anticoagulation
RecruitingPhase 2
- Moses Cone Hospital Operating Corporation dba Cone Health, Lebauer-Brodie Center for Cardiovascular Research, Greensboro
Assess the Safety and Efficacy of Sovateltide in Patients With Acute Cerebral Ischemic Stroke
RecruitingPhase 3
- Guilford Neurologic Associates Inc, Greensboro
An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)
RecruitingPhase 3
- Medication Management LLC, Greensboro
About Stroke
A stroke happens when there is a loss of blood flow to part of the brain. Immediate treatment may save a life and increase the chances for successful recovery.
More about Stroke on MedlinePlus
Stroke trials in other cities
- Chicago, IL34 studies
- New York City, NY30 studies
- Boston, MA30 studies
- Houston, TX24 studies
- Pittsburgh, PA22 studies
- Baltimore, MD21 studies
- Atlanta, GA20 studies
- Charleston, SC18 studies
- Washington, DC18 studies
- Philadelphia, PA17 studies
- Cleveland, OH15 studies
- Los Angeles, CA15 studies
Other studies in Greensboro
- Overweight12 studies
- Obesity12 studies
- Type 2 Diabetes6 studies
- Heart Failure6 studies
- Breast Cancer5 studies
- Cardiovascular Disease5 studies
- HIV4 studies
- Interstitial Lung Diseases4 studies
- Heart Attack4 studies
- Lung Cancer3 studies
- Idiopathic Pulmonary Fibrosis3 studies
- Atherosclerosis3 studies
From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.